Palatin Technologies Says Phase I Study Of Congestive Heart Failure Treatment, PL-3994, Met Primary Endpoint - Quick Facts

(RTTNews) - Palatin Technologies, Inc. (PTN | news | PowerRating | PR Charts ) announced the completion of a Phase I clinical trial of PL-3994, a natriuretic peptide receptor A agonist under development for treatment of acute decompensated congestive heart failure.

Dosing concluded with the successful achievement of the primary endpoint of the study, a prespecified reduction in systemic blood pressure.

For comments and feedback: contact editorial@rttnews.com Copyright(c) 2008 RealTimeTraders.com, Inc. All Rights Reserved

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index